Kyntra Bio Q1 net loss narrows as revenue rises

Kyntra Bio

11/05/2026 21:28

Overview

US biopharma firm's Q1 revenue from continuing ops rose yr/yr, net loss narrowed

Company reported $100.3 mln in cash and equivalents, funding runway into 2028

Phase 2 trial of FG-3246 in prostate cancer on track, Phase 3 roxadustat trial planned for 2H 2026

Outlook

Kyntra Bio expects interim analysis of Phase 2 FG-3246 trial in mCRPC in Q4 2026

Company plans to initiate pivotal Phase 3 roxadustat trial for LR-MDS in H2 2026

Kyntra Bio expects cash and equivalents to fund operations into 2028

Result Drivers

PIPELINE PROGRESS - Co cited steady enrollment in Phase 2 FG-3246 prostate cancer trial and preparations for Phase 3 roxadustat trial as key activities in Q1

CLINICAL DATA PRESENTATION - Positive results from investigator-sponsored study of FG-3246 in combination with enzalutamide presented at ASCO GU, informing Phase 2 trial design

Company press release: ID:nGNX8G8WjM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$3.70 mln
Q1 EPS
-$3.76
Q1 Net Income
-$15.20 mln
Q1 Net Income from Cont Ops
-$15.10 mln
Q1 Revenue from Cont Ops
$3.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Kyntra Bio Inc is $43.00, about 518.7% above its May 8 closing price of $6.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)